SAB4500112
Anti-C/EBP-β antibody produced in rabbit
affinity isolated antibody
Synonym(s):
AGP/EBP, C/EBP β, C/EBP-related protein 2, CCAAT/enhancer binding protein β, CEBPB
Product Name
Anti-C/EBP-β antibody produced in rabbit, affinity isolated antibody
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 36 kDa
species reactivity
human, rat, mouse
concentration
~1 mg/mL
technique(s)
ELISA: 1:10000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... CEBPB(1051)
Biochem/physiol Actions
CCAAT/enhancer-binding proteins (C/EBPs) regulate expression of various cytokines and chemokines such as, interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein-1 (MCP-1). C/EBP-β plays a vital role in the regulation of gluconeogenesis and adipogenesis gene expression. The encoded protein also modulates the gene expression of human immunodeficiency virus-1 (HIV-1) and other retroviruses (human T-cell leukemia virus type (HTLV-) and simian immunodeficiency viruses (SIV)). This is carried out by regulating various process, like C-C chemokine receptor type 5 (CCR5) expression, virus promoter activities, cytokine and chemokine production and virus protein function. C/EBPβ is involved in various cellular processes such as metabolism, development and differentiation. Overexpression of C/EBP-β mRNA has been observed in various types of cancers.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
General description
Anti-C/EBP-β Antibody detects endogenous levels of total C/EBP-β protein.
CCAAT/enhancer-binding protein-β (C/EBP-β) is encoded by the gene mapped to human chromosome 20q13.13. The encoded protein belongs to the C/EBP family. C/EBP-β is a leucine-zipper transcription factor and is highly expressed during the early stages of adipocyte development. Alternative splicing of C/EBP-β leads to the formation of three isoforms such as, C/EBPβ-1 with 346 amino acids, C/EBPβ-2 with 323 amino acid and C/EBPβ with 146 amino acids.
Immunogen
The antiserum was produced against synthesized peptide derived from human C/EBP-beta.
Immunogen Range: 201-250
Immunogen Range: 201-250
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
C/EBP?-1 promotes transformation and chemoresistance in Ewing sarcoma cells
Gardiner JD, et al.
Oncotarget, 8, 26013-26026 (2017)
CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection
Liu Y, et al.
Future Microbiology, 4, 299-321 (2009)
Genomic imbalances in Schistosoma-associated and non-Schistosoma-associated bladder carcinoma. An array comparative genomic hybridization analysis.
Armengol G
Cancer Genetics and Cytogenetics, 177, 16-19 (2007)
Dan Liu et al.
Nature communications, 9(1), 1739-1739 (2018-05-02)
Chemoresistance is a major unmet clinical obstacle in ovarian cancer treatment. Epigenetics plays a pivotal role in regulating the malignant phenotype, and has the potential in developing therapeutically valuable targets that improve the dismal outcome of this disease. Here we
Keito Okazaki et al.
Nature communications, 11(1), 5911-5911 (2020-11-22)
Transcriptional dysregulation, which can be caused by genetic and epigenetic alterations, is a fundamental feature of many cancers. A key cytoprotective transcriptional activator, NRF2, is often aberrantly activated in non-small cell lung cancers (NSCLCs) and supports both aggressive tumorigenesis and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service